YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Company Logo 281-Page Report Tracks Post-Pandemic Research Growth Across Pharma, Research and Industry/Cosmetic Users as 3D Assays, Automation and Immuno-oncology Reshape Drug Discovery Dublin, Oct. 07, 2026 (GLOBE NEWSWIRE) -- "Cell-Based…
WALTHAM, Mass., October 06, 2026--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it will host its 2026 Investor Day on Friday, November 13 at 9:00 a.m. ET. Presentations from members of Revvity's senior management team will p…
[Close-Up Shot of Scientists Hands typing Data in Laptop in Laboratory] Tom Werner Healthcare stocks underperformed the broader market in September, with the Health Care Select Sector SPDR Fund (XLV [https://seekingalpha.com/symbol/XLV]) f…
Revvity (RVTY) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.…
WALTHAM, Mass., October 02, 2026--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that it will release its third quarter 2026 financial results prior to market open on Tuesday, November 3, 2026. The Company will host a confere…
Q2 Earnings Review: Research Tools & Consumables Stocks Led by Avantor (NYSE:AVTR) Quarterly earnings results are a good time to check in on a company's progress, especially compared to its peers in the same sector. Today we are looking at…
Revvity (RVTY): Buy, Sell, or Hold Post Q2 Earnings? Revvity has been on fire lately. In the past six months alone, the company's stock price has rocketed 78%, reaching $150.93 per share. This was partly due to its solid quarterly results,…
Revvity, Inc. RVTY is well-positioned for growth, thanks to its strong product portfolio. The company is positioned for growth across diagnostics, life sciences and scientific informatics. Diagnostics remains a key growth engine, while new…
1 Unpopular Stock That Deserves Some Love and 2 Facing Headwinds Wall Street's bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate rel…
Revvity, Inc. RVTY recently launched the GSP T1D 3plex kit, a fully automated, CE-IVDR-certified multiplex autoantibody detection solution in Europe. The kit is designed to support population-wide screening for children at risk of developi…
Healthcare stocks were higher late Thursday afternoon, with the NYSE Healthcare Index increasing 0.9 PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
All three major US stock indexes fell in late-morning trading Thursday amid uncertainty in the Middl PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Fully automated, multiplex autoantibody detection solution, enabling population-wide screening programs DBS-based newborn screening platform enables simple and scalable sample collection Expands Revvity's diagnostic offerings from newborn…
Revvity (RVTY) has drawn fresh attention after recent share price gains, with the stock up about 15% over the past month and roughly 36% over the past 3 months. Over the past year, Revvity has shifted from lagging long term returns, with a…
Research Tools & Consumables Stocks Q2 Highlights: Agilent (NYSE:A) Let's dig into the relative performance of Agilent (NYSE:A) and its peers as we unravel the now-completed Q2 research tools & consumables earnings season. The life science…
Company Logo AI-enabled, microfluidic label-free detection is expanding in drug discovery, early diagnostics, food safety and environmental testing, driven by efficient, non-invasive, sustainable workflows. Dublin, Sept. 22, 2026 (GLOBE NE…
Company Logo High-content screening is advancing drug discovery and personalized medicine, driven by 3D models, advanced imaging and automated analytics, with opportunities in cancer research and organoids. Dublin, Sept. 22, 2026 (GLOBE NE…
Wall Street's major market averages finished mixed as Treasury yields rebounded, rekindling concerns about a deteriorating macroeconomic backdrop. The S&P 500 (SP500 [https://seekingalpha.com/symbol/SP500#source=url_first_level%3Amarket-ne…
[Wall Street sign in Lower Manhattan, NYC] georgeclerk Revvity (RVTY [https://seekingalpha.com/symbol/RVTY]) shares fell on Friday following a five-day winning streak as CFRA downgraded the life sciences company to Hold from Buy, citing a…
1 Momentum Stock with Promising Prospects and 2 Facing Headwinds Great things are happening to the stocks in this article. They're all outperforming the market over the last month because of positive catalysts such as a new product line, c…
[Wall Street street sign in Manhattan financial district] Alexey_Fedoren Stock index futures were higher on Wednesday as investors focused on the Federal Reserve's interest rate decision. Dow futures (INDU [https://seekingalpha.com/symbol/…
Revvity (RVTY) shares ended the last trading session 9.1% higher at $140.19. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 10.6% gain over the…
Wall street sign in New York City by f11photo via Shutterstock The S&P 500 Index ($SPX) (SPY) closed down by -0.45% on Tuesday, the Dow Jones Industrial Average ($DOWI) (DIA) closed down by -0.63%, and the Nasdaq 100 Index ($IUXX) (QQQ) cl…
Check out the companies making the biggest moves midday: Skyworks Solutions , Qorvo — The chipmakers popped, recovering from a sell-off in the previous session driven by safety concerns around artificial trade. Skyworks traded 10% higher,…
Q2 Rundown: Revvity (NYSE:RVTY) Vs Other Research Tools & Consumables Stocks As the Q2 earnings season comes to a close, it's time to take stock of this quarter's best and worst performers in the research tools & consumables industry, incl…
By Steven Ralston, CFA NYSE: VNRX READ THE FULL VNRX RESEARCH REPORT EXECUTIVE OVERVIEW VolitionRx Limited (NYSE: VNRX) continues to advance its multi-pillar epigenetics platform through mid-2026, generating a continued stream of clinical…
By Steven Ralston, CFA NYSE: VNRX READ THE FULL VNRX RESEARCH REPORT EXECUTIVE OVERVIEW VolitionRx Limited (NYSE: VNRX) continues to advance its multi-pillar epigenetics platform through mid-2026, generating a continued stream of clinical…
3 Healthcare Stocks That Fall Short From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advancements have benefited from elevated demand, and t…
Revvity, Inc. RVTY recently announced that it has entered into a definitive agreement to acquire Human Cell Design (HCD), a France-based biotechnology company focused on human cell models and preclinical research solutions for metabolic di…
Acquisition strengthens Revvity's position in human-relevant life sciences tools for next-generation GLP-1 and GPCR-targeting therapies for metabolic drug discovery Combines HCD's human pancreatic beta cell models with Revvity's capabiliti…
Company Logo 500-Page Report Spans 450 Data Tables Across Product, Species, Host Cell, and Application Segments as Human Recombinant Proteins Lead Demand Research Use Recombinant Protein MarketResearch Use Recombinant Protein Market Dublin…
Wall Street's major market averages finished lower on Friday after traders and investors digested the latest jobs data, which came in stronger than forecasted. The blue-chip Dow ended 0.5% lower, the benchmark S&P 500 slipped 0.3%, and the…
[Health Care Medical Concept] ogichobanov/iStock via Getty Images The healthcare sector (XLV [https://seekingalpha.com/symbol/XLV]) gained 4.91% in August, outperforming the broader S&P 500 (SPY [https://seekingalpha.com/symbol/SPY]), whic…
Revvity, Inc. RVTY is entering the second half of 2026 with stronger operating momentum. Raised guidance, double-digit Diagnostics growth and better cash generation have improved the earnings setup. The counterweight is valuation. RVTY alr…
Company Logo The global multiplex assays market is projected to grow from US$6.8 billion in 2025 to US$12.4 billion by 2030, at a 12.8% CAGR. North America leads with a 34% share, while Asia Pacific is the fastest-growing region at 15.5%;…
Thursday, September 3, 2026 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc. (AMZN), AbbVie Inc. (ABBV) and…